275 related articles for article (PubMed ID: 9703283)
1. Prostate-specific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumours.
Hall RE; Clements JA; Birrell SN; Tilley WD
Br J Cancer; 1998 Aug; 78(3):360-5. PubMed ID: 9703283
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression of androgen receptor and prostate-specific antigen in breast cancer.
Narita D; Raica M; Suciu C; Cîmpean A; Anghel A
Folia Histochem Cytobiol; 2006; 44(3):165-72. PubMed ID: 16977795
[TBL] [Abstract][Full Text] [Related]
3. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.
Honma N; Takubo K; Akiyama F; Sawabe M; Arai T; Younes M; Kasumi F; Sakamoto G
Histopathology; 2005 Aug; 47(2):195-201. PubMed ID: 16045781
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor expression in a Sri Lankan patient cohort with early breast carcinoma.
Wijesinghe HD; Wijesinghe GK; Mansoor Z; Vigneshwara S; Fernando J; Gunasekera D; Lokuhetty MDS
BMC Womens Health; 2020 Sep; 20(1):206. PubMed ID: 32928183
[TBL] [Abstract][Full Text] [Related]
5. Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women.
Sapino A; Righi L; Cassoni P; Papotti M; Gugliotta P; Bussolati G
Mod Pathol; 2001 Aug; 14(8):768-76. PubMed ID: 11504836
[TBL] [Abstract][Full Text] [Related]
6. Expression of androgen receptor, gross cystic disease fluid protein, and CD44 in salivary duct carcinoma.
Kapadia SB; Barnes L
Mod Pathol; 1998 Nov; 11(11):1033-8. PubMed ID: 9831198
[TBL] [Abstract][Full Text] [Related]
7. Progesterone-binding cyst protein (PBCP = GCDFP-24) and steroid hormone receptors as markers of differentiation in breast cancer. Inverse relation of distribution in normal and malignant tissue of the same breast.
Søreide JA; Lea OA; Kvinnsland S
Anticancer Res; 1991; 11(3):1323-6. PubMed ID: 1888167
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical analysis of pleomorphic lobular carcinoma: higher expression of p53 and chromogranin and lower expression of ER and PgR.
Radhi JM
Histopathology; 2000 Feb; 36(2):156-60. PubMed ID: 10672061
[TBL] [Abstract][Full Text] [Related]
9. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids.
Lee BH; Hecht JL; Pinkus JL; Pinkus GS
Am J Clin Pathol; 2002 May; 117(5):745-50. PubMed ID: 12090423
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach.
Lagendijk JH; Mullink H; van Diest PJ; Meijer GA; Meijer CJ
J Clin Pathol; 1999 Apr; 52(4):283-90. PubMed ID: 10474521
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical study of hormone receptor and hormone-regulated protein expression in phyllodes tumour: comparison with fibroadenoma.
Umekita Y; Yoshida H
Virchows Arch; 1998 Oct; 433(4):311-4. PubMed ID: 9808432
[TBL] [Abstract][Full Text] [Related]
12. Expression of steroid hormone receptors, their regulated proteins, and bcl-2 protein in myofibroblastoma of the breast.
Magro G; Bisceglia M; Michal M
Histopathology; 2000 Jun; 36(6):515-21. PubMed ID: 10849093
[TBL] [Abstract][Full Text] [Related]
13. Regulation of progesterone-binding breast cyst protein GCDFP-24 secretion by estrogens and androgens in human breast cancer cells: a new marker of steroid action in breast cancer.
Simard J; Dauvois S; Haagensen DE; Lévesque C; Mérand Y; Labrie F
Endocrinology; 1990 Jun; 126(6):3223-31. PubMed ID: 2351114
[TBL] [Abstract][Full Text] [Related]
14. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.
Gonzalez LO; Corte MD; Junquera S; Bongera M; Rodriguez JC; Vizoso FJ
Histopathology; 2007 Jun; 50(7):866-74. PubMed ID: 17543076
[TBL] [Abstract][Full Text] [Related]
15. Regulation of GCDFP-15 expression in human mammary cancer cells.
Loos S; Schulz KD; Hackenberg R
Int J Mol Med; 1999 Aug; 4(2):135-40. PubMed ID: 10402478
[TBL] [Abstract][Full Text] [Related]
16. Gross cystic disease fluid protein-15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple-negative breast cancer.
Huo L; Zhang J; Gilcrease MZ; Gong Y; Wu Y; Zhang H; Resetkova E; Hunt KK; Deavers MT
Histopathology; 2013 Jan; 62(2):267-74. PubMed ID: 22963676
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical localization of gross cystic disease fluid protein-15, -24 and -44 in ductal carcinoma in situ of the breast: relationship to the degree of differentiation.
Selim AA; El-Ayat G; Wells CA
Histopathology; 2001 Aug; 39(2):198-202. PubMed ID: 11493337
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen- and androgen-like steroids.
Hackenberg R; Schulz KD
J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):113-7. PubMed ID: 8603031
[TBL] [Abstract][Full Text] [Related]
19. Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes.
Darb-Esfahani S; von Minckwitz G; Denkert C; Ataseven B; Högel B; Mehta K; Kaltenecker G; Rüdiger T; Pfitzner B; Kittel K; Fiedler B; Baumann K; Moll R; Dietel M; Eidtmann H; Thomssen C; Loibl S
BMC Cancer; 2014 Jul; 14():546. PubMed ID: 25070172
[TBL] [Abstract][Full Text] [Related]
20. Occult breast carcinoma presenting with axillary lymph node metastases: follow-up of eleven patients.
Matsuoka K; Ohsumi S; Takashima S; Saeki T; Aogi K; Mandai K
Breast Cancer; 2003; 10(4):330-4. PubMed ID: 14634511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
